Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 11, 2008, Pages 1136-1142

  Kim, Hee Seung ^a   Park, Noh Hyun ^a,b   Chung, Hyun Hoon ^a   Kim, Jae Weon ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Epithelial ovarian cancer; Lymph node metastasis; Serum CA 125 level

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 56649092575     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802478158     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Kim HS, Kim TH, Chung HH, Kim JW, Park NH, Song YS, et al. Clinical analysis for the prognostic factors in patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery. Korean J Gynecol Oncol. 2008;19:75-80.
3. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999;64:5-10.
4. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer. 1998;83:1555-60.
5. Onda T, Yoshikawa H, Yokota H, Yasugi T, Taketani Y. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer. 1996;78:803-8.
6. Di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol. 1996;62:360-5.
7. Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer. 2000;10:435-42.
8. Triller J, Goldhirsch A, Fuchs WA. Value of computed tomography for the assessment of lymph node metastases in ovarian cancer. Rofo. 1984;141:35-9.
9. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234-8.
10. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, 2nd, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-43.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
12. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560-6.
13. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501-5.
14. Tsumura N, Sakuragi N, Hareyama H, Satoh C, Oikawa M, Yamada H, et al. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer. 1998;79:526-30.
15. Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, et al. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? Gynecol Oncol. 2008;108:428-32.
16. La Fianza A, Campani R, Dore R, Babilonti L, Tateo S. The clinical value of computed tomography and lymphography in detecting lymph node metastases from epithelial ovarian cancer. Rofo. 1992;157:162-6.
17. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest. 2003;55:130-4.
18. Sugiyama T, Nishida T, Ushijima K, Sato N, Kataoka A, Imaishi K, et al. Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized tomography or magnetic resonance imaging. J Obstet Gynaecol. 1995;21:551-6.
19. Cho YH, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878-82.
20. Parazzini F, Valsecchi G, Bolis G, Guarnerio P, Reina S, Polverino G, et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. Gynecol Oncol. 1999;74:7-11.
21. Saygili U, Guclu S, Uslu T, Erten O, Ture S, Demir N. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* study. J Surg Oncol. 2002;81:132-7.
22. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007;96:1817-22.